The Post Menopausal Osteoporosis drugs in development market research report provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Post Menopausal Osteoporosis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued products.

GlobalData tracks 52 drugs in development for Post Menopausal Osteoporosis by 50 companies/universities/institutes. The top development phase for Post Menopausal Osteoporosis is phase iii with 25 drugs in that stage. The Post Menopausal Osteoporosis pipeline has 49 drugs in development by companies and three by universities/ institutes. Some of the companies in the Post Menopausal Osteoporosis pipeline products market are: Biocon, Jiangsu Hengrui Medicine and Takeda Pharmaceutical.

The key targets in the Post Menopausal Osteoporosis pipeline products market include Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or RANKL or CD254 or TNFSF11), Parathyroid Hormone Receptor, and Sclerostin (SOST).

The key mechanisms of action in the Post Menopausal Osteoporosis pipeline product include Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or RANKL or CD254 or TNFSF11) Inhibitor with 23 drugs in Pre-Registration. The Post Menopausal Osteoporosis pipeline products include five routes of administration with the top ROA being Subcutaneous and seven key molecule types in the Post Menopausal Osteoporosis pipeline products market including Monoclonal Antibody, and Recombinant Peptide.

Post Menopausal Osteoporosis overview

Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure, and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues.

For a complete picture of Post Menopausal Osteoporosis’s pipeline drug market, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.